(Q37894998)

24 August 2017

1 reference

title

Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review (English)

1 reference

24 August 2017

0 references

1 reference

1 reference

Augusto Caraceni

2

0 references

Sebastiano Mercadante

series ordinal

1

object named as

Sebastiano Mercadante

1 reference

24 August 2017

1 July 2011

1 reference

24 August 2017

1 reference

24 August 2017

25

1 reference

24 August 2017

5

1 reference

24 August 2017

504-515

1 reference

Strategies to manage the adverse effects of oral morphine: an evidence-based report.

24 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid rotation for toxicity reduction in terminal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid switching: a systematic and critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid rotation for cancer pain: rationale and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid switching and rotation in primary care: implementation and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Establishing "best practices" for opioid rotation: conclusions of an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid rotation: the science and the limitations of the equianalgesic dose table

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Morphine and alternative opioids in cancer pain: the EAPC recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioids switching with transdermal systems in chronic cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Rapid switching between transdermal fentanyl and methadone in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid plasma concentrations during a switch from transdermal fentanyl to methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Rapid switching from morphine to methadone in cancer patients with poor response to morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

The role of methadone in opioid rotation-a Polish experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Controlled-release oxycodone and morphine in cancer related pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Morphine and oxycodone hydrochloride in the management of cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Methadone titration in opioid-resistant cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Long‐term cancer pain management in morphine pre‐treated and opioid naive patients with transdermal fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

A systematic review of opioid conversion ratios used with methadone for the treatment of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Hyperalgesia and opioid switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Accuracy in equianalgesic dosing. conversion dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

Opioid equianalgesic tables: are they all equally dangerous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269216311406577

21 January 2018

Identifiers

DOI

10.1177/0269216311406577

1 reference

24 August 2017

1 reference

PubMed ID

21708857